2015 Grants Announced
2015-2016 Request for Proposals Now Available
Just announced last week, our 2015-2016 RFP is now available for Team Science Awards, Young Investigator Awards, Academic-Industry Partnership Awards (for Established Investigators) and a Special Opportunity Team Science Award in Acral Melanoma. In September we will have a unique, second RFP focused on Special Opportunity Awards. Applications will be accepted beginning in November.
New Committee Members
We have added several new members to our committees that help guide our decision making and offer strategic counsel for scientific, clinical, and policy matters. These include the Grant Review Committee, Scientific Advisory Panel, and Medical Advisory Panel.
DEVELOPMENT AND COLLABORATION
Following another successful May, marking Melanoma Awareness Month, MRA has focused on extending the messages of prevention and awareness beyond the month. To that end, partnerships with L’Oréal Paris, Sports Authority, Neiman Marcus, and Lands’ End have helped raise awareness to reduce the risk of melanoma, as well as more than $300,000 for melanoma research. See more of our corporate partners.
Top 5 Again!
MRA is pleased to be included in Genetic Engineering & Biotechnology News’ 2015 list of top 35 grant-giving disease foundations, based on the percentage of overall funds going to research. In fact, for the second year in a row, MRA is ranked among the top 5 in the nation. Your donation to MRA helps support groundbreaking research. Please consider donating today!
Explaining the Latest Treatments
The treatment options for patients with advanced melanoma have changed rapidly in the last few years, but it can be difficult for patients to make sense of it all. We launched new online content that explains all of the FDA-approved therapies. It’s also available in Spanish.
MRA is pleased to partner with the Society for Immunotherapy of Cancer and the Global Resource for Advancing Cancer Education for an Immunotherapy Patient Forum in November at National Harbor, MD. Registration is now open.
In the News
Chief Science Officer Louise Perkins was interviewed by the Washington Post discussing the latest breakthrough treatments. She was also featured in Allure talking about UPF clothing and how it offers protection from the sun.
UPDATES FROM MRA
AACR Meeting Highlights Developments in Melanoma Research
Investigators supported by the Melanoma Research Alliance (MRA) once again headlined sessions at this year’s annual meeting of the American Association for Cancer Research (AACR), held April 18-22 in Philadelphia. Read more.
Chief Science Officer Featured in AACR Leadership Newsletter
MRA’s Louise Perkins was interviewed for a feature in the AACR’s Women In Cancer Research newsletter. Read the interview.
MRA-Funded Research Suggests Immunotherapy Combined with Radiation May Represent a Promising Approach
Treating metastatic melanoma with immunotherapies that target the CTLA4 and PD-1 pathways and radiation therapy suggests that the combination boosts the immune system’s attack on the disease. The research, led by a multidisciplinary team of investigators from the University of Pennsylvania, including MRA Pilot Award recipient Ramesh Rengan (now at the University of Washington), was published in the journal Nature. Read more about this research.
Save the Date for Leveraged Finance Fights Melanoma
Join the biggest names in leveraged finance for an evening of networking on May 19 to benefit MRA. Join us.
- The Promise of Immunotherapy
- It's THAT Worth It Thunderclap
- Thought Leadership and Conferences
- The Sunscreen Innovation Act
- MRA & SU2C - Tom Hanks & Hillary Kind
- Skinceuticals MRA 'Spots' Video
- MRA Rings Closing Bell at NYSE
- Jeff Rowbottom at the Forbes Healthcare Summit
- MRA-SU2C Melanoma Dream Team
- Bruce Springsteen PSA
- Accelerating Progress for a Cure
- Style Network-MRA PSA
- Cancer 101 Briefing Series: Today's Cancer Clinical Trials. Tomorrow's Cures.